4,4-二氟环己甲酸 | 122665-97-8

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酸
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 中文名称: 4,4-二氟环己甲酸
• 中文别名: 4,4-二氟环己烷羧酸；4,4-二氟环己酸；4,4-二氟环己基甲酸；HXFA
• 英文名称: 4,4-difluorocyclohexanecarboxylic acid
• 英文别名: 4,4-difluorocyclohexane-1-carboxylic acid；4,4-difluorocyclohexylcarboxylic acid；4,4-difluorocyclohexanoic acid
• CAS: 122665-97-8
• 化学式: C₇H₁₀F₂O₂
• mdl: MFCD03788493
• 分子量: 164.152
• InChiKey: HYIUDFLDFSIXTR-UHFFFAOYSA-N

物化性质

• 熔点：
  103-107 °C
• 沸点：
  241.1±40.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、甲醇
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会发生分解，目前未有已知危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916209090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其存放在阴凉、干燥处。确保工作间有良好的通风或排气装置。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 4,4-Difluorocyclohexanecarboxylic acid
CAS-No. : 122665-97-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H10F2O2
Molecular Weight : 164,15 g/mol
Component Concentration
4,4-Difluorocyclohexanecarboxylic acid
CAS-No. 122665-97-8 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 103 - 107 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

4,4-二氟环己甲酸是一种用于合成大环内酯类抗生素的二取代环己烷羧酸。

反应信息

• 作为反应物：
  描述：

  4,4-二氟环己甲酸 在 苯硅烷 、 zinc diacetate 、 sodium hydroxide 作用下， 以 水 、 氯苯 、 甲苯 为溶剂， 生成 马拉维若
  参考文献：
  名称：

  实用的羧酸催化还原胺化

  摘要：

  我们报道了使用羧酸作为标称亲电子试剂的胺的还原烷基化反应。该两步反应利用了苯基硅烷的双重反应性，涉及硅烷介导的酰胺化，然后是 Zn(OAc) 2催化的酰胺还原。该反应适用于多种胺和羧酸，并已得到大规模证明（305 mmol 胺）。抗逆转录病毒药物马拉韦罗的聚合合成中体现了叔酰胺中间体和仲酰胺中间体的还原速率差异。机理研究表明，酰胺化步骤中残留的 0.5 当量羧酸负责生成具有增强反应性的硅烷还原剂，从而可以还原以前在锌/苯基硅烷体系中不反应的仲酰胺。

  DOI：

  10.1039/d0sc02271c
• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 生成 4,4-二氟环己甲酸
  参考文献：
  名称：

  SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

  摘要：

  本发明涉及的是具有以下化学式I的化合物：其中R1、R2、R3、R4、R5、R6、R7、R8、R9和n的定义如描述中所定义的化合物。该发明还涉及制备这些化合物的过程，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的使用。

  公开号：

  US20090111830A1
• 作为试剂：
  描述：

  4,4-二氟环己甲酸 、 3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenyl-1-propanamine 在 4,4-二氟环己甲酸 作用下， 生成 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
  参考文献：
  名称：

  [EN] TROPANE DERIVATIVES USEFUL IN THERAPY
  [FR] DERIVES DU TROPANE UTILES EN THERAPIE

  摘要：

  本发明提供式(I)的化合物：其中R1为C3-6环烷基，可选地被一个或多个氟原子取代，或C1-6烷基，可选地被一个或多个氟原子取代，或C3-6环烷基甲基，可选地被一个或多个氟原子取代；R2为苯基，可选地被一个或多个氟原子取代，以及其药学上可接受的盐和溶剂，以及制备该化合物所用的中间体，包含该化合物的组合物和用途的制备过程。

  公开号：

  WO2001090106A2

文献信息

• Design and Synthesis of Novel Dasatinib Analogues
  作者：G. Buchappa、K. Durgaprasad、B. Suneelkumar、P. Baby Rani、K. Ravi Babu、A.K.S. Bhujanga Rao、P. Aparna

  DOI：10.14233/ajchem.2016.19650

  日期：——

  Design, synthesis, characterization and in vitro biological assay of a series of novel carboxylic acid and amino acid analogs of dasatinib (1) as anticancer agents are reported. Some of the synthesized analogs were identified as potent Src/Abl kinase inhibitors with greater antiproliferative activity against K652 and T315I cancer cell lines. The synthetic process involves condensation of N-(2-chloro-6-methylphenyl)-2-[[6-[4(-1-pipearazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide with carboxylic acids in the presence of dicyclohexylcarbodiimide and oxyma in organic solvent medium. Compounds were characterized and tested for anticancer activity on leukemia cancer cell lines K562 and Baf3/T315. Analogues of lactic acid, mandalic acid, leucine and proline have shown promising antiproliferative activity compared to dasatinib.

  报道了以1型药物dasatinib为原型的系列新型羧酸和氨基酸类似物的设计、合成、表征以及体外生物学分析，作为抗癌药物。其中一些合成的类似物被鉴定为强效Src/Abl激酶抑制剂，对K652和T315I癌细胞系具有更高的抗增殖活性。合成过程涉及在有机溶剂介质中，以二环己基碳二亚胺和氧马酸作为催化剂，将N-(2-氯-6-甲基苯基)-2-[[6-[4(-1-哌拉嗪基]-2-甲基-4-嘧啶基]氨基]-5-噻唑羧酰胺与羧酸进行缩合反应。化合物经过表征并测试其对白血病癌细胞系K562和Baf3/T315的抗癌活性。与dasatinib相比，乳酸、苯乙酮酸、亮氨酸和脯氨酸类似物显示出有前景的抗增殖活性。
• [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015048306A1

  公开（公告）日：2015-04-02

  The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.

  该发明提供了一种甾醇C14-去甲基酶的抑制剂，这是一种新系列基于4-氨基吡啶的首选抑制剂，通过基于结构的药物设计以及结构-性质关系（SPR）分析来瞄准Trypanosoma cruzi CYP51（TcCYP51）而开发的。筛选起始点LP 10（KD < 42 nM；EC50为0.65 μΜ）已经经过优化，产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性，大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性（在1 μΜ下<50%的抑制）。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外，通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51（TbCYP51）同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
• [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
  申请人：UNIV EMORY

  公开号：WO2019183133A1

  公开（公告）日：2019-09-26

  This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

  本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方，用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病，或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外，这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
• Photoinduced decarboxylative borylation of carboxylic acids
  作者：Alexander Fawcett、Johan Pradeilles、Yahui Wang、Tatsuya Mutsuga、Eddie L. Myers、Varinder K. Aggarwal

  DOI：10.1126/science.aan3679

  日期：2017.7.21

  283 Light facilitates the replacement of carboxylic acids with boron esters in the absence of metal catalysts. The conversion of widely available carboxylic acids into versatile boronic esters would be highly enabling for synthesis. We found that this transformation can be effected by illuminating the N-hydroxyphthalimide ester derivative of the carboxylic acid under visible light at room temperature

  照亮碳硼化的道路 硼取代基提供了多种反应性，并且它们的效用已经出现在制药领域。福西特等人。表明可见光可以诱导硼酸酯取代羧酸基团，这将有助于将它们引入各种化合物中。一旦酸被邻苯二甲酰亚胺取代基活化，它们就可以在酰胺溶剂中在光照下与儿茶酚硼烷二聚体反应，无需催化剂或其他添加剂。该反应似乎通过光引发后的自由基链增长进行。科学，这个问题 p。283 Light 有助于在没有金属催化剂的情况下用硼酯替代羧酸。将广泛可用的羧酸转化为多功能硼酸酯将非常有助于合成。我们发现，在二硼试剂双（儿茶酚）二硼存在下，在室温下，在可见光下照射羧酸的 N-羟基邻苯二甲酰亚胺酯衍生物，可以实现这种转化。简单的后处理可以分离频哪醇硼酸酯。实验证据表明，硼基自由基中间体参与了该过程。该方法通过伯、仲和叔烷基羧酸以及各种天然产物羧酸的转化来说明，从而证明其广泛的实用性和官能团耐受性。
• Organocatalytic decarboxylative alkylation of <i>N</i>-hydroxy-phthalimide esters enabled by pyridine-boryl radicals
  作者：Liuzhou Gao、Guoqiang Wang、Jia Cao、Dandan Yuan、Cheng Xu、Xuewen Guo、Shuhua Li

  DOI：10.1039/c8cc06152a

  日期：——

  The decarboxylative alkylation of N-hydroxyphthalimide (NHPI) based reactive esters with olefins has been achieved via an organocatalytic strategy. Control experiments and density functional theory calculations suggest that these reactions involve a boryl-radical mediated decarboxylation pathway, which is different from the single electron transfer involved in decarboxylative alkylation reactions reported

  N-羟基邻苯二甲酰亚胺（NHPI）基反应性酯与烯烃的脱羧烷基化已通过有机催化策略实现。对照实验和密度泛函理论计算表明，这些反应涉及硼基自由基介导的脱羧途径，该途径不同于先前报道的脱羧烷基化反应中涉及的单电子转移。这种无金属的脱羧烷基化反应具有良好的功能相容性，并且通过烷基和芳基羧酸衍生物的转化说明了广泛的底物范围。